For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

FOXO4-DRI: origin, design and research history

Research Library › Bioregulators & Thymic

FOXO4-DRI is a synthetic D-retro-inverso peptide derived from part of the FOXO4 protein, designed to interfere with the binding between FOXO4 and the tumor-suppressor protein p53 in senescent cells. It was developed by Peter de Keizer and colleagues at Erasmus MC in Rotterdam and published in Cell in 2017. As of 22 Oct 2026 it is not approved anywhere and remains preclinical.

Key facts

TypeSynthetic D-retro-inverso (DRI) peptide
Derived fromA segment of the transcription factor FOXO4
First described2017, Cell (Baar et al.)
Developed byPeter de Keizer and colleagues, Erasmus MC, Rotterdam
Designed targetThe FOXO4-p53 protein interaction in senescent cells
Regulatory status (Oct 2026)Not approved anywhere; no clinical trials listed; preclinical

Who developed it

FOXO4-DRI was designed by molecular biologist Peter de Keizer and colleagues at Erasmus MC, the university medical center in Rotterdam, the Netherlands. The work, led by first author Marjolein Baar, was published in the journal Cell in March 2017 after more than four years of development [1, 2, 3].

De Keizer later co-founded Cleara Biotech, which launched in 2018 to develop FOXO4-based peptides and is now based in Utrecht [4, 5].

What it was designed to target

Senescent cells are cells that have permanently stopped dividing but have not died. The Rotterdam team reported that in such cells the transcription factor FOXO4 binds p53, a protein that can trigger programmed cell death (apoptosis), and holds it in the nucleus [1, 6].

FOXO4-DRI copies the part of FOXO4 involved in that interaction and was designed to compete with it, disrupting the FOXO4-p53 link. It is built in D-retro-inverso form: mirror-image (D) amino acids assembled in reverse order. This arrangement mimics the side-chain layout of the natural sequence while resisting breakdown by common enzymes, and the peptide was engineered to enter cells [1, 6]. This is a proposed mechanism from laboratory and animal research; it has not been tested in people.

Why it was created

The project aimed to find a way to remove senescent cells selectively while sparing healthy ones, a research strategy known as senolytics [3]. Earlier senolytic candidates were mostly repurposed small-molecule drugs; the Rotterdam group instead set out to design a peptide around a specific protein-protein interaction found in senescent cells [1]. De Keizer described the planned first human study as a safety trial in glioblastoma, an aggressive brain tumor, reflecting a research program in oncology [3]. Cleara’s later candidates, CL04177 and CL04183, are FOXO4-based peptides directed at late-stage cancer research [5].

Research timeline

  • Mar 2017: Baar et al. publish the FOXO4-DRI paper in Cell [1]
  • 2018: Cleara Biotech launches [4]
  • Sep 2022: Cleara raises $2.5 million in seed financing [5]
  • Oct 2025: A drug database lists CL04183 as preclinical [7]
  • Sep 2026: Cleara’s website lists no clinical trials [8]

Regulatory status as of October 2026

As of 22 Oct 2026, FOXO4-DRI is not approved by the FDA or by any other regulator, and no human trial of it has been reported. Cleara Biotech’s website, last updated in September 2026, describes laboratory and animal work and lists no clinical trials; its successor candidate CL04183 was listed as preclinical in October 2025 [7, 8].

FOXO4-DRI is not named on the World Anti-Doping Agency’s 2026 Prohibited List. WADA’s S0 category covers pharmacological substances with no current approval for human therapeutic use [9].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who developed FOXO4-DRI?

FOXO4-DRI was developed by Peter de Keizer and colleagues at Erasmus MC in Rotterdam and published in Cell in 2017.

Is FOXO4-DRI FDA approved?

No. As of October 2026 it is not approved anywhere and has not entered human clinical trials.

What does DRI stand for?

DRI stands for D-retro-inverso, a design built from mirror-image D-amino acids arranged in reverse order to resist enzymatic breakdown.

What is FOXO4?

FOXO4 is a forkhead box O transcription factor, a protein that regulates gene activity and, in senescent cells, was reported to bind p53.

What is Cleara Biotech?

Cleara Biotech is a Dutch company co-founded by Peter de Keizer, launched in 2018 and now based in Utrecht, that develops FOXO4-based peptides; its candidates were preclinical as of 2026.

Has FOXO4-DRI been tested in humans?

No human trial has been reported as of October 2026. A first safety study in glioblastoma was discussed in 2017, but no such trial has been reported since.

Sources

  1. Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132-147. doi:10.1016/j.cell.2017.02.031. Link
  2. DutchNews.nl. News report on the Erasmus MC FOXO4-DRI study. 27 Mar 2017. Link
  3. Medical Xpress. News report on the Erasmus MC FOXO4-DRI study and planned first trial. Mar 2017. Link
  4. Fight Aging! Cleara Biotech launches to develop senolytic therapies based on FOXO4-DRI. 9 Jul 2018. Link
  5. Cleara Biotech (Business Wire press release). Cleara Biotech raises $2.5 million in seed financing to advance FOXO4 therapeutics pipeline. 27 Sep 2022. Link
  6. Nature Research Highlight. Senescent cells cleared out. Nature. 2017;543:593. Link
  7. Patsnap Synapse. CL-04183 drug profile (Cleara Biotech; highest phase: preclinical). Updated 18 Oct 2025. Link
  8. Cleara Biotech. Company website (platform, lead candidates CL04177 and CL04183), last modified 16 Sep 2026. Link
  9. World Anti-Doping Agency. 2026 Prohibited List (S0 non-approved substances). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top